ALX Oncology Announces Upcoming Virtual Investor Conference Participation

Rhea-AI Summary

BURLINGAME, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced participation in two virtual investor conferences. The first is the UBS 2021 Global Healthcare Virtual Conference on May 24 at 4:00 PM ET, featuring a podium presentation. The second is the Jefferies 2021 Virtual Healthcare Conference on June 2 at 1:30 PM ET, structured as a fireside chat with analyst Michael Yee. Webcasts for both events will be available on the ALX Oncology website with replays accessible for 90 days.

ALX Oncology focuses on CD47 checkpoint therapies, with lead candidate ALX148 showing promising clinical results.

BURLINGAME, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.

UBS 2021 Global Healthcare Virtual Conference
Format: Podium presentation
Date: Monday, May 24
Time: 4:00 PM Eastern Time
Webcast link: Available here

Jefferies 2021 Virtual Healthcare Conference
Format: Fireside chat with analyst, Michael Yee
Date: Wednesday, June 2
Time: 1:30 PM Eastern Time
Webcast link: Available here

A live webcast of the UBS podium presentation and Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcasts will be archived for up to 90 days following the presentation dates.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications as well as MDS and AML. For more information, please visit ALX Oncology’s website at www.alxoncology.com.

FAQ

When is ALX Oncology participating in the UBS 2021 Global Healthcare Virtual Conference?

ALX Oncology will participate in the UBS 2021 Global Healthcare Virtual Conference on May 24, 2021, at 4:00 PM Eastern Time.

What format will the Jefferies 2021 Virtual Healthcare Conference take for ALX Oncology?

The Jefferies 2021 Virtual Healthcare Conference will feature a fireside chat with analyst Michael Yee on June 2, 2021, at 1:30 PM Eastern Time.

Where can I watch ALX Oncology's investor conference presentations?

You can watch ALX Oncology’s investor conference presentations live on their website under the Investors section, and replays will be available for 90 days.

What is ALX148 and its significance for ALX Oncology?

ALX148 is ALX Oncology's lead product candidate, designed to block the CD47 checkpoint pathway, showing promising clinical responses in various cancer types.

What is the focus of ALX Oncology in cancer treatment?

ALX Oncology focuses on developing therapies that block the CD47 checkpoint pathway to enhance cancer treatment and improve patient outcomes.